In a recent study, researchers aimed to determine the proportion of patients with non-small cell lung cancer who developed hyperprogressive disease following treatment with immunotherapy.

Conferences

Improving provider response to adverse events through an algorithm.

News

In a recent study, researchers aimed to determine the proportion of patients with non-small cell lung cancer who developed hyperprogressive disease following treatment with immunotherapy.
In a recent study, researchers evaluated data on 33 solid cancer types in order to determine whether a certain mutational burden threshold could predict patients’ responses to immune checkpoint therapy.
The 70-gene signature assay for early breast cancer provides physicians with actionable information and may be associated with adjuvant therapy decisions.

Patients with metastatic cancer who are treated with an anti-programmed death (PD-1) therapy are at an increased risk for neurological complications, according to a study published in JAMA Neurology (October 2017;74[10]:1216-1222).

Read More

Research in Review

Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.

In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product.

-----

Related Content

Read More

Chimeric antigen receptor (CAR) T-cells may elicit responses in solid cancers by inducing cancer cell death and the release of tumor antigens that could stimulate T-cell activity, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published in Proceedings of the National Academy of Sciences (published online April 26, 2017; doi:10.1073/pnas.1705327114).

-----

Read More

Subscribe to Immuno-Oncology